Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis (MS) Relapsing Remitting”

245 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 245 results

Testing effectiveness (Phase 2)UnknownNCT01466114
What this trial is testing

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Who this might be right for
Relapsing-remitting Multiple SclerosisSecondary-progressive Multiple SclerosisPrimary-progressive Multiple Sclerosis
University of California, Los Angeles 64
Post-approval studies (Phase 4)Study completedNCT02048072
What this trial is testing

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

Who this might be right for
Multiple SclerosisAutonomic Nervous System Dysfunction
Jochen Vehoff 33
Testing effectiveness (Phase 2)Study completedNCT00882999
What this trial is testing

Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Eli Lilly and Company 245
Testing effectiveness (Phase 2)Study completedNCT02782858
What this trial is testing

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GeNeuro SA 270
Not applicableStudy completedNCT04997148
What this trial is testing

Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 116
Testing effectiveness (Phase 2)Study completedNCT00879658
What this trial is testing

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals 297
Early research (Phase 1)UnknownNCT02903537
What this trial is testing

Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive
Fundació Institut Germans Trias i Pujol 16
Testing effectiveness (Phase 2)Study completedNCT00168701
What this trial is testing

Efficacy and Safety of BG00012 in MS

Who this might be right for
Multiple Sclerosis
Biogen 260
Not applicableWithdrawnNCT01539395
What this trial is testing

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
MSDx, Inc.
Early research (Phase 1)WithdrawnNCT00674141
What this trial is testing

Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment

Who this might be right for
MS Patient With Relpasing Remitting Attacks
Hadassah Medical Organization 10
Testing effectiveness (Phase 2)Looking for participantsNCT05359653
What this trial is testing

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Who this might be right for
Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+4 more
University of California, San Francisco 74
Not applicableUnknownNCT00914758
What this trial is testing

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Washington Neuropsychology Research Group 1
Post-approval studies (Phase 4)Study completedNCT01705236
What this trial is testing

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Who this might be right for
Relapsing Remitting Multiple Sclerosis RRMS
Novartis Pharmaceuticals 87
Not applicableStudy completedNCT01142492
What this trial is testing

A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 403
Testing effectiveness (Phase 2)Study completedNCT00395317
What this trial is testing

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis
GlaxoSmithKline 343
Not applicableLooking for participantsNCT07426991
What this trial is testing

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Who this might be right for
Multiple SclerosisRemitting-Relapsing Multiple SclerosisPrimary Progressive Multiple Sclerosis+3 more
Heinrich-Heine University, Duesseldorf 837
Large-scale testing (Phase 3)Looking for participantsNCT05834855
What this trial is testing

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDemyelinating Autoimmune Diseases, CNS+3 more
Amsterdam UMC, location VUmc 200
Post-approval studies (Phase 4)WithdrawnNCT02675413
What this trial is testing

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Washington University School of Medicine
Not applicableLooking for participantsNCT07292480
What this trial is testing

Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Centre Hospitalier Universitaire de Nīmes 84
Not applicableStudy completedNCT02247310
What this trial is testing

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

Who this might be right for
Multiple Sclerosis, Relapsing Remitting
Bayer 498
Load More Results